FEB 2 2027
Gilead Sciences — Yeztugo (lenacapavir) $GILD
for HIV-1 pre-exposure prophylaxis (PrEP) — once-weekly oral formulation
Accepted JUN 15 2026.
About
HIV pre-exposure prophylaxis (PrEP) is a highly effective strategy to prevent HIV infection, but current daily pills require strict adherence and long-acting injections need clinic visits. Yeztugo (lenacapavir) is a weekly oral pill that works by blocking the HIV capsid, a critical shell that protects the virus's genetic material. This once-weekly option could offer a more convenient prevention method, potentially helping people who struggle with daily pill routines.
Pivotal trial
The goal of this clinical study is to learn more about the study drug lenacapavir (LEN), safety, tolerability, and pharmacokinetics (how LEN is absorbed, modified, distributed, and removed from the body of the participants) of once-yearly intramuscular for HIV pre-exposure prophylaxis (PrEP) in people with an indication for PrEP. The primary objective of this study is to evaluate the pharmacokinetics (PK) and the safety and tolerability of intramuscular (IM) every 12 months (Q12M) LEN for PrE...
Source: ClinicalTrials.gov
Also in development
Drug Watch — recent news on Yeztugo
- Gilead Sciences Sees Yeztugo Powering HIV Growth as Oncology Pipeline Advances - Yahoo Finance
- Gilead’s HIV PrEP franchise hits $1B quarterly sales, but analysts question Yeztugo durability - Fierce Pharma
- Gilead’s Yeztugo beats forecasts as HIV PrEP franchise exceeds $1B - Endpoints News
- [Gilead Sciences Q2 2026 Earnings Call] Gilead PrEP Sales Top $1 Billion as Yeztugo Persistence Hits 70%; HIV Growth Raised to 10% - finance.biggo.com
- Gilead earnings loom: Can Yeztugo, Trodelvy offset acquisition costs? By Investing.com - Investing.com Nigeria
Sponsor Watch — recent news on Gilead Sciences
- Why Is Gilead Sciences (GILD) Widening Lenacapavir Access Across 120 Countries?
- Gilead Expands Lenacapavir Licensing Agreements to Include Once-Yearly HIV Prevention Formulation
- Gilead Accelerates Global Access Planning for Investigational Once-Yearly Lenacapavir for HIV Prevention
- Gilead Expands Lenacapavir Access With New PAHO Deal in Latin America
- Gilead Sciences Sees Yeztugo Powering HIV Growth as Oncology Pipeline Advances